IP Library Granted Patent US 12,138,233
Granted Patent B2
US 12,138,233 · App. 17/180,991 · Granted Nov 12, 2024

Methods of treating idiopathic hypersomnia

Inventors: Franck Skobieranda (Palo Alto, CA); Dan Chen (Los Altos, CA); Amanda Leigh Sterkel (Santa Clara, CA); Cuiping Chen (Palo Alto, CA); Patricia Chandler (Palo Alto, CA)
Assignee: Jazz Pharmaceuticals Ireland Limited
A61K31/19A61K9/08A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,138,233
App. No.
17/180,991
Granted
Nov 12, 2024
Kind
B2
Abstract

The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate).

Claims (30)

1. A method of treating idiopathic hypersomnia in a patient in need thereof, the method comprising:

a twice daily dosing regimen, comprising (a) administering to an adult patient with idiopathic hypersomnia an initial daily dose of less than or equal to about 4.5 grams of a mixed salt oxybate divided equally or unequally into 2 doses; and (b) titrating the daily dose to provide a therapeutically effective amount of the mixed salt oxybate, wherein the maximum daily dose is about 9 grams divided equally or unequally into 2 doses; or

a once daily dosing regimen, comprising (a) administering to an adult patient with idiopathic hypersomnia an initial daily dose of less than or equal to about 3 grams of the mixed salt oxybate; and (b) titrating the daily dose to provide a therapeutically effective amount of the mixed salt oxybate, wherein the maximum daily dose is about 6 grams;

wherein the mixed salt oxybate comprises about 5%-40% sodium oxybate, about 10%-40% potassium oxybate, about 5%-30% magnesium oxybate, and about 20%-80% of calcium oxybate (% mol. eq.).

2. The method of claim 1 , wherein the mixed salt oxybate comprises about 8% sodium oxybate, about 23% potassium oxybate, about 21% magnesium oxybate and about 48% calcium oxybate (% mol. eq.).

3. The method of claim 1 , wherein the initial daily dose is from about 0.5 g to about 4.5 g of the mixed salt oxybate.

4. The method of claim 1 , wherein the initial daily dose is about 4.5 g of the mixed salt oxybate.

5. The method of claim 1 , wherein the titration step (b) comprises administering ascending doses of the mixed salt oxybate.

6. The method of claim 5 , wherein the dose is increased by about 0.5 g to 1.5 g per night per week.

7. The method of claim 1 , wherein the titration step (b) is from about 1 week to about 10 weeks.

8. The method of claim 1 , wherein about 4.5 g of the mixed salt oxybate is administered per day.

9. The method of claim 1 , wherein about 6 g of the mixed salt oxybate is administered per day.

10. The method of claim 9 , wherein about 3 g of the mixed salt oxybate is administered twice per day.

11. The method of claim 1 , wherein about 7.5 g of the mixed salt oxybate is administered per day.

12. The method of claim 11 , wherein about 3.75 g of the mixed salt oxybate is administered twice per day.

13. The method of claim 1 , wherein about 9 g of the mixed salt oxybate is administered per day.

14. The method of claim 13 , wherein about 4.5 g of the mixed salt oxybate is administered twice per day.

15. The method of claim 1 , wherein the mixed salt oxybate is administered at bedtime and about 2 h-4 h after the bedtime administration.

16. The method of claim 1 , wherein about 4.5 g-6.0 g of the mixed salt oxybate is administered once per day.

17. The method of claim 1 , wherein the patient is administered the mixed salt oxybate at least 2 h after the patient's last meal.

18. The method of claim 1 , wherein about 3 g to about 6 g is administered per day.

19. The method of claim 1 , wherein the patient is an adult patient.

20. A method of treating idiopathic hypersomnia in a patient in need thereof, the method comprising:

a twice daily dosing regimen, comprising (a) administering to an adult patient with idiopathic hypersomnia an initial daily dose of less than or equal to about 4.5 grams of a mixed salt oxybate divided equally or unequally into 2 doses; and (b) titrating the daily dose to provide a therapeutically effective amount of the mixed salt oxybate, wherein the maximum daily dose is about 9 grams divided equally or unequally into 2 doses;

wherein the mixed salt oxybate comprises about 5%-40% sodium oxybate, about 10%-40% potassium oxybate, about 5%-30% magnesium oxybate, and about 20%-80% of calcium oxybate (% mol. eq.).

21. The method of claim 20 , wherein the titration step (b) comprises administering ascending doses of no more than about 1.5 grams/night per week of the mixed salt oxybate.

22. A method of treating idiopathic hypersomnia in a patient in need thereof, the method comprising:

a once daily dosing regimen, comprising (a) administering to an adult patient with idiopathic hypersomnia an initial daily dose of less than or equal to about 3 grams of a mixed salt oxybate; and (b) titrating the daily dose to provide a therapeutically effective amount of the mixed salt oxybate, wherein the maximum daily dose is about 6 grams;

wherein the mixed salt oxybate comprises about 5%-40% sodium oxybate, about 10%-40% potassium oxybate, about 5%-30% magnesium oxybate, and about 20%-80% of calcium oxybate (% mol. eq.).

23. The method of claim 22 , wherein the titration step (b) comprises administering ascending doses of no more than about 1.5 grams/night per week of the mixed salt oxybate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2022
From: SKOBIERANDA, FRANCK; CHEN, DAN; STERKEL, AMANDA LEIGH; CHEN, CUIPING; CHANDLER, PATRICIA
To: JAZZ PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 059218/0134 →
SECURITY AGREEMENT Recorded May 5, 2021
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056151/0010 →
Continuity (6)
Provisional Application 63142738 · Jan 28, 2021
Provisional Application 63088902 · Oct 7, 2020
Provisional Application 63069811 · Aug 25, 2020
Provisional Application 62993381 · Mar 23, 2020
Provisional Application 62979667 · Feb 21, 2020
Related Publication 20220008367A1 · Jan 13, 2022
Cited By (2)
US 12,440,449 US 12,582,622